Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Phase 1 × Acrocephalosyndactylia × infigratinib × Clear all

Phase

Phase 1 2 Phase 2 1

Status

Withdrawn 1 Completed 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1 Breast 1

Conditions

Urinary Bladder Neoplasms 2 Acrocephalosyndactylia 2 Uterine Cervical Neoplasms 1 Tumor With Alterations of the FGF-R 1 Neoplasms 1 Lung Neoplasms 1 Liver Neoplasms 1 Cholangiocarcinoma 1 Breast Neoplasms 1

Interventions

infigratinib 2 pemigatinib 1 exemestane 1 erdafitinib 1 Fulvestrant 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04972253 2022-08-10

(BLASST)-3

Dana-Farber Cancer Institute

Phase 1 Withdrawn

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT01928459 2020-12-09

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Novartis

Phase 1 Completed

Acrocephalosyndactylia, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡